No abstract available.
Polycythemia Vera* ; Polycythemia* ; Thrombocythemia, Essential*

No abstract available.
Myocardial Infarction* ; Polycythemia Vera* ; Polycythemia*

A study on 16 patients (male: 14; ages of 50-78) with the primary polycythemia vera treated by the specific guidelines has shown that the number of erythrocyte in patients with polycythemia vera after a duration of suffering the disease was increased, followed by gradual reduction and was at low level at last. The specific clinical signs can change comprised the number of hypertension can be reduced, the number of thrombocyte, and leukocyte can be slightly increased and should be treated in the first stage and second stage but should not be treated in the third stage
Polycythemia Vera ; Erythrocytes

No abstract available.
Adult* ; Cerebral Infarction* ; Humans ; Polycythemia Vera* ; Polycythemia*

Polycythemia vera (PV) was first described nearly 120 years ago. In the subsequent century, the clinical syndrome of PV, its natural history, its treatment, and many critical pathogenetic features of the disease were characterized. The discovery of the Janus-associated kinase - 2 mutation JAK2 V617F and the characterization of its role in myeloproliferative neoplasms have substantially changed the diagnostic paradigm for PV, and have potential to lead to new therapy and new pathogenetic insights.
Natural History ; Phosphotransferases ; Polycythemia ; Polycythemia Vera

No abstract available.
Liver Cirrhosis* ; Liver* ; Polycythemia Vera* ; Polycythemia*

No abstract available.
Polycythemia Vera* ; Renal Artery Obstruction*

MPS comprised 4 disease's forms, such as: Chronic myelogenous leukemia (CLM), polycythemia vera (PV), essential thrombocytothemia (ET) and idiopathic myelofibrosis (IMF). From 1985 to May-2001 at Friendship hospital, authors have followed up a group of 86 patients with MPS and some remarks had been drawn out: Some disease's forms of MPS can transform each other, such as: +PV transformed in to CML: 10.00%; +PV transformed in to ET: 16.67%; +IMF transformed in to CML: 66.67%; +ET transformed in to CLM: 8.0%. Some case in MPS, although have not yet truly transformed, but have some changes, as such: +ET with concomitantly increasing erythrocytes: 4.0%; +IMF with concomitantly increasing platelets: 33.33%; +CML with concomitantly increasing platelets: 21.43%; Authors have also mentioned many interesting issues about the way of transformation, the last diagnosis for those disease's forms and the prognosis of these transformations
Leukemia, Myeloid ; Polycythemia Vera ; Syndrome

No abstract available.
Cerebral Infarction ; Diffusion Magnetic Resonance Imaging ; Polycythemia ; Polycythemia Vera

The association of skin tumors and long-term use of hydroxyurea is recently recognized. We report a case of a patient who developed squamous cell carcinoma on the face during long-term treatment with hydroxyurea for polycythemia vera. As hydroxyurea is frequently used to treat myeloproliferative diseases, we suggest the clinical awareness of the increased risk of skin cancers in patients with long-term hydroxyurea therapy.
Carcinoma, Squamous Cell* ; Humans ; Hydroxyurea* ; Polycythemia Vera ; Skin ; Skin Neoplasms